As part of an effort to increase its cell therapy manufacturing, Iovance Biotherapeutics is planning to add hundreds of new ...

Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for ...

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat ...

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks ...

Sonnet BioTherapeutics (SONN) announced that the United States Patent and Trademark Office has issued a Notice of Allowance to the Company for ...

David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance ...

Raymond James Financial Inc. acquired a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 1,563,296 ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 13.80%, which has investors questioning if this is right time to buy.

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Arcutis Biotherapeutics, Inc.’s ARQT share price has surged by 12.31%, which has investors questioning if this is right time to sell.

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1 ...